United States Patent 7,030,095: Scope, Claim Construction, and Patent Landscape for Topical Pediculicide/Ovicides Based on Spinosyns Stabilized with PVM/MA Decadiene Crosspolymers
US 7,030,095 claims a topical method for controlling adult and ova of Anoplura (lice) by applying a composition to skin and/or hair. The inventive hinge is a spinosyn/spinosad pediculicidal + ovicidal active system stabilized with polyvinyl methyl ether/maleic anhydride (PVM/MA) decadiene crosspolymers, with additional dependent structure locking in specific solvent, excipient, and particle-size limits.
What do the independent claims cover?
Claim 1: Method with active + PVM/MA decadiene crosspolymer particle-size limit
Claim 1 is a method claim with three essential building blocks:
- Actives: one or more agents selected from spinosad (and/or spinosyn/spinosyn A/spinosyn D; the claim text lists “Spinosad, Spinosyn, Spinosyn A, Spinosyn D and mixtures”).
- Use format: topically applying to one or more of skin and hair a composition comprising a solution of the effective amount of the active(s).
- Stabilizer identity and property: “one or more stabilizers” comprising PVM/MA decadiene crosspolymers, where the stabilizers have particle size < 75 μm.
Scope characteristics
- Locks active family to spinosyn/spinosad-related actives.
- Locks stabilizer chemistry to PVM/MA decadiene crosspolymer.
- Adds a particle-size threshold that can materially narrow design-around options (lower or higher particle distributions, or alternative particle forms).
Claim 2: Method with same core, but solvent recipe constraints
Claim 2 keeps the same core as claim 1 and adds that the solution solvent consists of one or more of:
- benzyl alcohol
- pentylene glycol
- isopropyl alcohol
- hexylene glycol
- butylene glycol
- dipropylene glycol
Scope characteristics
- Narrows formulations by requiring solvent components from that list (or allowing inclusion of any subset “one or more”).
Claim 3: Broader excipient-enabled formulation (moisturizer, emulsion stabilizers, antioxidants, pH adjuster, etc.)
Claim 3 maintains the same active + PVM/MA decadiene crosspolymer requirement and expands the formulation feature set to include:
- moisturizers
- emulsion stabilizers
- emulsifying agents
- conditioning agents
- antioxidants
- pH adjuster
Scope characteristics
- Still anchors to spinosyn/spinosad + PVM/MA decadiene crosspolymer.
- Leaves excipient choices open at claim level for these categories (until dependent claims specify examples).
Claim 12: Composition embodiment with explicit % w/w
Claim 12 is the only claim you provided with full quantitative composition percentages and a defined mixture ratio for spinosyn A/spinosyn D:
- 44% water
- 1.1% PVM/MA decadiene crosspolymer
- 3% propylene glycol
- 3% cetearyl alcohol
- 0.9% ceteareth-20
- 4.17% stearalkonium chloride
- 10% benzyl alcohol
- 6% hexylene glycol
- 4% pentylene glycol
- 20% isopropyl alcohol
- 2.19% mixture of spinosyn A and spinosyn D in approx 85:15 (w/w)
- 0.1% BHT
- 1.29% sodium hydroxide (10% solution)
Scope characteristics
- This claim is the most “locked” in practical manufacturing terms because it fixes:
- the stabilizer level (1.1%)
- a specific solvent mixture
- specific excipient exemplars across multiple categories
- the spinosyn A:D mixture ratio (85:15)
What do the dependent claims lock in (and how does that affect infringement risk)?
Claims 4 to 11 add specific substitutions for categories in claim 3:
- Claim 4 (moisturizer): propylene glycol
- Claim 5 (emulsion stabilizer): mixture of cetyl and stearyl alcohols
- Claim 6 (emulsifying agent): Ceteareth-20
- Claim 7 (conditioning agent): stearalkonium chloride
- Claim 8 (antioxidant): BHT (butylated hydroxytoluene)
- Claim 9 (pH adjuster): sodium hydroxide
- Claim 10: method further comprising viscosity increasing agent
- Claim 11 (viscosity increasing agent): mixture of cetyl and stearyl alcohols
Practical claim-construction implications
- A product that uses spinosad/spinosyns + PVM/MA decadiene crosspolymer but swaps specific excipients could still read on claim 3 (because claim 3 allows category members without specifying identities).
- If a product matches only claim 1 (active + PVM/MA decadiene crosspolymer with particle size <75 μm) but uses different moisturizing/emulsifying/antioxidant/pH systems, it can still be within claim 1/2 depending on solvent choices.
- If a product matches all specific dependent excipients, it risks reading on claims 3-11 as a set, and on claim 12 if it matches the full % recipe and spinosyn A:D ratio.
Claim scope map: what must be present, and what can vary
| Claim |
Must-have active |
Stabilizer constraint |
Solvent constraint |
Excipients locked by claim text |
| 1 |
Spinosad/spinosyns (A/D etc.) |
PVM/MA decadiene crosspolymer; particle size <75 μm |
“Solution” format only (no list) |
No specific excipients required |
| 2 |
Same as claim 1 |
Same as claim 1 |
Solvent must be from benzyl alcohol / glycols / alcohols list |
No specific excipients required |
| 3 |
Same as claim 1 |
PVM/MA decadiene crosspolymer (no particle size limitation stated in claim 3 as provided) |
No explicit solvent list in your text |
Must include categories: moisturizer, emulsion stabilizer, emulsifier, conditioning agent, antioxidant, pH adjuster |
| 4-9 |
Same as claim 3 |
Same as claim 3 |
Not added |
Each locks example ingredient for its category |
| 10-11 |
Same as claim 3 |
Same as claim 3 |
Not added |
Adds viscosity increasing agent; then locks cetyl+stearal alcohols |
| 12 |
Same as claim 3 |
Fixed at 1.1% |
Fixed multi-solvent composition (benzyl alcohol, glycols, isopropyl alcohol) |
Locks full % w/w and spinosyn A:D ratio (~85:15) |
Where does infringement likely concentrate (formulation engineering perspective)?
1) The stabilizer is the core design point
To avoid claims 1/3, a manufacturer must generally avoid at least one of:
- using spinosyn/spinosad as defined, or
- using PVM/MA decadiene crosspolymer, or
- for claim 1 specifically, achieving particle size <75 μm for the stabilizer.
If the stabilizer is replaced with a different polymer system that does not fall within “PVM/MA decadiene crosspolymers,” claim coverage weakens.
2) Particle size matters for claim 1
Even if the same polymer family is used, claim 1 adds a quantitative particle size requirement (<75 μm), which is a measurable manufacturing parameter that can create non-infringement outcomes if the stabilizer distribution stays above the threshold (assuming measurement and product specs align with how the claim is interpreted).
3) Solvent selection matters for claim 2
Claim 2 limits solvent selection to a closed genus/list of specific alcohols and glycols. A formulation that retains the active and polymer but uses a different solvent system outside the list can avoid claim 2 while still potentially falling under claim 1 or claim 3 depending on whether the claim 1 particle-size limit is met.
4) Dependent claims create “trapdoors” for “known excipient recipes”
Many topicals use propylene glycol, benzyl alcohol, ceteareth-20, stearalkonium chloride, and BHT. Those exact choices align with dependent claims 4-9 and 12. A portfolio company targeting these actives with a similar vehicle has a higher probability of matching multiple dependent claims even if it alters one or two other components.
Patent landscape: how US 7,030,095 likely sits relative to broader pediculicide protections
1) “Spinosyn-based pediculicides” is a mature actives moat
Spinosyn-based pediculicidal and ovicidal therapy is established commercially, with patent families historically focused on:
- composition and formulation approaches
- delivery systems
- ovicidal efficacy and adult-louse killing performance
US 7,030,095 is an example of vehicle-and-stabilizer-focused claim strategy: it does not broadly claim “spinosad for lice,” but instead narrows to a specific spinosyn/spinosad active set formulated with a specific stabilizer chemistry (PVM/MA decadiene crosspolymers), including particle-size and specific excipient recipe constraints in dependent claims.
2) Likely competitive infringement scenario
A competitor launching a spinosyn-based lice topical with:
- PVM/MA decadiene crosspolymer as stabilizer (even at different concentrations),
- similar multi-solvent alcohol/glycol base,
- conventional emollient/emulsifier/conditioning/antioxidant and pH system,
faces a concentrated risk because:
- claim 3 covers the presence of multiple excipient categories without needing exact identities
- dependent claims 4-9 and 12 cover common exemplars and an explicit percent formulation
3) Likely design-around paths
From the claim text you provided, the most straightforward design-around approaches (in a formulation program) are:
- swap out PVM/MA decadiene crosspolymer for a stabilizer not encompassed by the term, or
- keep the polymer but adjust stabilizer particle distribution so claim 1 particle size is not met (<75 μm), or
- keep the polymer and actives but change the solvent set so the composition does not meet claim 2’s solvent list (even if claim 1 or 3 might remain at issue), or
- use category-equivalent excipients but avoid the listed exemplars where dependent claims are asserted (though claim 3 still requires the categories, not necessarily those exemplars).
What is the competitive “claim coverage sweet spot”?
A product matches the claim set most strongly when it reproduces:
- Active: spinosyn mixture consistent with spinosyn A and D inclusion (as covered by “spinosyn A” and “spinosyn D” / spinosad)
- Stabilizer: PVM/MA decadiene crosspolymer, with particle size <75 μm for claim 1
- Excipient categories (claim 3): moisturizer, emulsion stabilizer, emulsifier, conditioning agent, antioxidant, pH adjuster
- Exemplars (claims 4-9): propylene glycol, cetyl+stearal alcohol mixture, Ceteareth-20, stearalkonium chloride, BHT, NaOH
- Optional viscosity agent (claims 10-11): viscosity increasing agent such as cetyl+stearal alcohol mixture
- Vehicle recipe (claim 12): the explicit % composition and the spinosyn A:D ratio (~85:15)
That combination is exactly what claim 12 provides as a quantified blueprint.
Key Takeaways
- US 7,030,095 claims topical lice control (adults and ova) using spinosyn/spinosad actives plus PVM/MA decadiene crosspolymer stabilizers.
- Claim 1 is narrowed by PVM/MA decadiene crosspolymer particle size <75 μm.
- Claim 2 narrows further by locking the solvent set to specific alcohols and glycols.
- Claim 3 broadens by requiring multiple excipient categories but leaves specific identities open until dependent claims.
- Claims 4-11 lock common excipient exemplars (propylene glycol, cetyl/stearal alcohol mixture, Ceteareth-20, stearalkonium chloride, BHT, NaOH) and a viscosity agent.
- Claim 12 is the highest-risk embodiment because it fixes a full quantitative formulation plus an ~85:15 spinosyn A:D ratio.
FAQs
1) Does the patent claim a single composition or a method scope?
It claims methods (claims 1-11) for topical application, plus an additional claim that provides an explicit composition recipe in the form you provided (claim 12).
2) What is the single most important formulation element for claim coverage?
The stabilizer chemistry: PVM/MA decadiene crosspolymers, including a particle-size <75 μm requirement in claim 1.
3) Can a competitor avoid claim 2 without changing actives or stabilizer chemistry?
Yes in principle by using a solvent system that does not use one or more of the specified components (benzyl alcohol, specific glycols, specific alcohols listed in claim 2), but the product could still be exposed under claim 1 or claim 3.
4) If a product matches the categories in claim 3 but not the specific excipients in claims 4-9, is it still at risk?
Yes. Claim 3 only requires the presence of excipient categories; the specific identities in claims 4-9 are additional limitations.
5) Is claim 12 the most restrictive claim?
Yes. It fixes explicit % values across the vehicle and specifies a spinosyn A/spinosyn D weight ratio (approx. 85:15), creating the tightest match requirement.
References
[1] United States Patent 7,030,095.
